CLIN CHEM:游离甲状腺素测量的标准化-采用更加统一的参考区间

2017-10-20 MedSci MedSci原创

IFCC甲状腺功能标准化委员会旨在规范游离甲状腺素(FT 4)的免疫测定。近日,国际杂志 《CLIN CHEM》在线发表一项关于游离甲状腺素测量的标准化的研究。研究人员开发了基于平衡透析和质谱法的国际系统可追踪的常规参考测量程序(RMP)。

IFCC甲状腺功能标准化委员会旨在规范游离甲状腺素(FT 4)的免疫测定。近日,国际杂志 《CLIN CHEM》在线发表一项关于游离甲状腺素测量的标准化的研究。研究人员开发了基于平衡透析和质谱法的国际系统可追踪的常规参考测量程序(RMP)。 研究人员使用RMP对标准化和参考间隔(RI)进行了测试,并同时也由13个制造商进行测量。同时验证了重新校准结果的适用性,以满足从生物变异确定的偏倚(3.3%)和总误差(8.0%)的技术参数。但是,由于这些参数严格,研究人员分别将其扩大到10%和13%。报告RI的结果与重新校准结果一样。研究使用参数统计程序估计了除了1 RI之外,并假设由RMP确定的RI适合于通过重新校准测定。 研究结果显示13个重新校准的测定中有12个具有偏倚,满足95%的置信度的10%的技术参数,对于7种测定,甚至适用于3.3%的技术参数。只有1个检测符合13%的总误差参数。重新校准将标准化测定方法的CV从13%降低到5%。机关有一些限制,概念验证研究证实了我们关于RI的假设。 研究表明重新校准到RMP显著减小FT 4免疫偏倚,使得由RMP确定的RI在12.5%范围内适合于常规使

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758816, encodeId=23941e5881609, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a86337383877, createdName=108807375_62823139, createdTime=Thu Jun 21 12:41:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510583, encodeId=08631510583e3, content=<a href='/topic/show?id=0032663e6ff' target=_blank style='color:#2F92EE;'>#游离甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66376, encryptionId=0032663e6ff, topicName=游离甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0410217579, createdName=xqptu, createdTime=Sun Oct 22 09:41:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546899, encodeId=8b7915468998e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Oct 22 09:41:00 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758816, encodeId=23941e5881609, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a86337383877, createdName=108807375_62823139, createdTime=Thu Jun 21 12:41:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510583, encodeId=08631510583e3, content=<a href='/topic/show?id=0032663e6ff' target=_blank style='color:#2F92EE;'>#游离甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66376, encryptionId=0032663e6ff, topicName=游离甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0410217579, createdName=xqptu, createdTime=Sun Oct 22 09:41:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546899, encodeId=8b7915468998e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Oct 22 09:41:00 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1758816, encodeId=23941e5881609, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a86337383877, createdName=108807375_62823139, createdTime=Thu Jun 21 12:41:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510583, encodeId=08631510583e3, content=<a href='/topic/show?id=0032663e6ff' target=_blank style='color:#2F92EE;'>#游离甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66376, encryptionId=0032663e6ff, topicName=游离甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0410217579, createdName=xqptu, createdTime=Sun Oct 22 09:41:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546899, encodeId=8b7915468998e, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Sun Oct 22 09:41:00 CST 2017, time=2017-10-22, status=1, ipAttribution=)]